Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
about
Role of RANKL inhibition in osteoporosisAlendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal womenEtidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal womenRisedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal womenRisedronate for the prevention and treatment of postmenopausal osteoporosisPercutaneous vertebroplasty versus balloon kyphoplasty for treatment of osteoporotic vertebral compression fracture: a meta-analysis of randomised and non-randomised controlled trialsThe aging spine: new technologies and therapeutics for the osteoporotic spineEuropean guidance for the diagnosis and management of osteoporosis in postmenopausal womenBisphosphonates: mechanism of action and role in clinical practiceOsteoporosis and its managementIbandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosisGuidelines on the management of osteoporosis associated with chronic liver diseaseAn Increased Risk of Osteoporosis during Acquired Immunodeficiency SyndromeEffect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonatesTreating osteoporosisBisphosphonates can prevent recurrent hip fracture and reduce the mortality in osteoporotic patient with hip fracture: A meta-analysisPrevention and treatment of bone fragility in cancer patientManaging Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral ResearchPostmenopausal syndromePercutaneous vertebroplasty and percutaneous balloon kyphoplasty for osteoporotic vertebral compression fracture: A metaanalysisDenosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patientsThe discovery and development of selective estrogen receptor modulators (SERMs) for clinical practiceOsteoporosis Treatment: When to Discontinue and When to Re-startUpdates on mechanism of action and clinical efficacy of risedronate in osteoporosisTreatment of primary osteoporosis in menBisphosphonate drug holiday: choosing appropriate candidatesDenosumab: mechanism of action and clinical outcomesDo bisphosphonates cause femoral insufficiency fractures?Parathyroid hormone and parathyroid hormone-related protein analogs as therapies for osteoporosisBone anabolics in osteoporosis: Actuality and perspectivesAtypical Femur Fractures in Patients Treated with Bisphosphonates: Identification, Management, and PreventionUpper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug useUpdate on bazedoxifene: a novel selective estrogen receptor modulatorRheumatology: 15. OsteoporosisRecent Clinical Trials in Osteoporosis: A Firm Foundation or Falling Short?Factors affecting adherence to osteoporosis medications: a focus group approach examining viewpoints of patients and providersOsteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club.Imminent fracture risk.A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year dataOdanacatib for the treatment of postmenopausal osteoporosis.
P2860
Q21195417-FBFC2DCB-825E-4930-B627-484892946006Q24242258-2412B113-06EC-4CFE-853D-8391E25AC1ADQ24242665-EDF89489-E3AE-4FE7-A202-B31CA2E1A071Q24242674-B8B7EEBE-B504-4D23-A8E3-DFD6EB676481Q24245000-C6A000EE-77C7-4788-BCA1-9FCFB65718AEQ24603953-3514EA7A-9382-41E0-BD69-BAADA746467BQ24609687-02A173CC-2BEC-4C2A-9181-09C630AD6741Q24612411-2FE95734-B9EF-446A-87AF-C4F10B8E2527Q24644708-128615A9-93AA-4E3F-99F3-182A88BB55BBQ24670075-03966FA0-CCF2-4055-B013-1BFE779D102EQ24680238-118631F3-5A92-4308-B5AF-C259A2B9DC5FQ24685899-4FEAD3F5-90AD-4989-96EB-15078671BA15Q24791238-400FA730-6E95-4420-8170-E394D4B48B01Q24802074-C5460435-8C6F-4E25-867B-DF106F19CB57Q26747363-8CD75322-FB51-4D67-8E1B-7F4BD7C64B7FQ26749442-D2DED64D-AA7E-43CE-A92C-A202E05D17E0Q26775765-5735377E-249F-499A-85B2-EF4EA1412FEAQ26782621-619908BD-4D5A-4B95-9D0F-C368F7845227Q26795412-4F75AA79-B6D8-4BFE-B2EB-424BBF4BDD0CQ26801273-F8496EDC-0684-4AC3-B36E-CCD573774488Q26824762-66CDCB9E-0FDE-43DE-9811-202F711C727EQ26830744-D3B84EC5-38FA-4174-9E70-E082AD2827A7Q26858980-8096BF0C-166B-4CE1-8175-B142B7EE4A75Q26864549-B5C9E482-1D7E-4352-A3D6-6B1E4903235CQ26991748-9FF71070-60BD-4F89-B561-3C8FBDE9E45CQ27004682-E7C13199-0509-45E7-90E7-06E1767FEA2FQ27015899-618E7381-5CE7-44EC-AC1C-F98F4040B80FQ27021396-E398A215-11E3-44A6-BDC2-390F10E9EF34Q27024513-FEF75F0B-1EE8-4D2A-9CA7-2DEB6812112FQ27691122-6B388B9A-A3A8-4E6D-8617-ADC3B5B2C5BBQ28079133-D343B66D-FFF7-4D36-B0E0-7D91A24281B4Q28218365-B39A6D6D-EDD9-4C88-A4A0-2193C994C7AAQ28258998-F27DAF85-DE1E-4016-9CFB-E867991F811AQ28344803-77CB236B-C6C8-4A0D-9500-90B444EB263FQ28552191-8563BB6B-47F9-4155-AC05-628F200D948FQ28744535-9B7252DF-EE9E-4D38-955A-F7C196DE6A8EQ30235173-4A65B0FF-31F8-4C2C-8A08-D3019DAC825DQ30235569-4D0CA2B9-603D-4BAD-9F8A-92DB07E1AF5DQ30577427-75727F47-A359-44B2-A3C1-C5F27BA8C523Q30683504-EBD7C984-CD52-4D00-B5C3-12F4F3B8BD12
P2860
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Effects of risedronate treatme ...... te Therapy (VERT) Study Group.
@en
type
label
Effects of risedronate treatme ...... te Therapy (VERT) Study Group.
@en
prefLabel
Effects of risedronate treatme ...... te Therapy (VERT) Study Group.
@en
P2093
P356
P1476
Effects of risedronate treatme ...... te Therapy (VERT) Study Group.
@en
P2093
C D McKeever
C H Chesnut
D W Axelrod
E F Eriksen
H K Genant
M S Hoseyni
P D Miller
P304
P356
10.1001/JAMA.282.14.1344
P407
P577
1999-10-01T00:00:00Z